Deric Geng is a technology specialist in the Intellectual Property Department. He joined the firm in 2008.
Past Experience
Prior to joining the firm, Dr. Geng was a research investigator at the Novartis Institute for Biomedical Research in Cambridge, Massachusetts. His primary research involved discovering drug-like molecules that modulated protein targets and pathways implicated in diabetes and metabolic diseases.
From 2002 to 2004, Dr. Geng was a US Army Breast Cancer Research Foundation Postdoctoral Fellow in Dr. Samuel Danishefsky's laboratory at the Memorial Sloan-Kettering Cancer Center in New York, where he accomplished the total synthesis of anticancer agent aigialomycin D and worked as a part of a team to design and accomplish the total synthesis of fully synthetic gp120 glycopeptides as anti-HIV vaccine agents.
Dr. Geng obtained his Ph.D. degree from State University of New York at Stony Brook in 2002, where he designed and synthesized taxoid and taxane-free anticancer agents in Professor Iwao Ojima's laboratories.
Professional Activities
Dr. Geng is a member of the American Chemical Society.
Honors and Awards
- US Army Breast Cancer Foundation Postdoctoral Fellow
- SUNYSB President's Award to Distinguished Doctoral Students
Selected Journal Publications and Patents
- Ojima, I. et al., “Design, synthesis, and biological evaluation of new-generation taxoids,” Journal of Medicinal Chemistry, 2008, 51, 3203-3221.
- Krauss, I. J. et al, “Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody,” Journal of the American Chemical Society, 2007, 129, 11042-11044.
- Warren, J.D.; Geng, X.; Danishefsky, S. J., “Synthetic glycopeptides-based vaccines,” Topics in Current Chemistry 2007, 267 (Glycopeptides and Glycoproteins), 109-141.
- Geng, X.; Danishefsky, S. J. “Total synthesis of aigialomycin D”, Organic Letters 2004, 6, 413-416.
- Geng, X., Yang, Z.-Q., Danishefsky, S. J. “Synthetic development of radicicol and cycloproparadicicol: highly promising anticancer agents targeting Hsp90”, Synlett 2004, 8, 1325-1333.
- Geng, X.; Dudkin, V. Y.; Mandal, M.; Danishefsky, S. J. “Glycopeptides (2): In pursuit of carbohydrate-based HIV vaccines, Part 2: the total synthesis of high-mannose-type gp120 fragments-evaluation of strategies directed to maximal convergence”, Angewandte Chemie International Edition 2004, 43, 2562-2565.
- Geng, X.; Geney, R.; Pera, P.; Bernacki, R. J.; Ojima, I. “Design and synthesis of de novo cytotoxic alkaloids through mimicking taxoid skeleton”, Bioorganic Medicinal Chemistry Letters 2004, 14, 3491-3494.
- Geng, X.; Miller, M. L.; Lin, S.; Ojima, I. “Synthesis of novel C2-C3’N-linked macrocyclic taxoids by means of highly regioselective heck macrocyclization”, Organic Letters 2003, 5, 3733-3736.
- Danishefsky, S. J.; Dudkin, V.; Geng, X.; Mandal, M.; Kraus, I., Preparation of glycoconjugates and glycans of gp120 specific antigen for treating HIV infection, 2006, US 2006229432.
- Danishefsky, S. J.; Dudkin, V.; Geng, X.; Mandal, M.; Olson, W.; Orlova, M., Preparation of gp120 glycopeptide dimers for treatment of HIV-1, 2006, WO 2006017180.
- Danishefsky, S. J.; Yang, Z.-Q.; Geng, X.; Chou, T.-C.; Rosen, N., Preparation of aigialomycin D, radicicol and monocillin I and their macrocyclic analogs for use in pharmaceutical compositions as antitumor agents, 2005, WO 2005061481.
- Danishefsky, S. J.; Dudkin, V.; Geng, X.; Mandal, M., Glycopeptide gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof, 2004, WO 2004050711.
